Literature DB >> 8902565

Proliferation of epithelia of noninvolved mucosa in patients with head and neck cancer.

V M Kotelnikov1, J S Coon, S Taylor, J Hutchinson, W Panje, D D Caldareill, S LaFollette, H D Preisler.   

Abstract

BACKGROUND: Morphologically noninvolved mucosa in patients with head and neck cancer is altered by carcinogens. These alterations may include chromosome alterations, gene mutations, and other molecular abnormalities which may explain very high incidence of second tumors in this group of patients. The purpose of this study was to investigate the in vivo proliferative characteristics in epithelial tissues adjacent to the tumor in a series of patients with head and neck cancer.
METHODS: Twenty-one patients with head and neck tumors received IV infusions of iododeoxyuridine (IdUrd) and/or bromodeoxyuridine (BrdUrd). Surgical specimens containing normal-appearing epithelium adjacent to the tumor were selected and stained with the respective monoclonal antibody. The percentage of S-phase cells (labeling index, LI) was counted in the basal and suprabasal layers of the epithelium.
RESULTS: In 27 samples of oral epithelium obtained from 14 previously untreated patients, labeled (S-phase) cells were predominantly located in suprabasal layers with LI 31.6 +/- 3.1% (range 13.5-73.2%). In contrast, the LI of the basal layer was very low: 1.6 +/- 0.2% (range 0.5%-8.8%). There was no statistically significant difference between normal appearing and dysplastic samples (p > 0.05). In 10 samples obtained from 7 patients whose biopsies were studied 2 days to 2 month after concomitant radiation and chemotherapy, the LI of the oral mucosa basal layer was significantly higher (21.0 +/- 4.1%, range 6.3-39.2%). The LI of the suprabasal layer in treated patients was 14.3 +/- 2.4% (range 5.9-31.1%). The LI of nasal pseudostratified epithelium (4 samples) was 11.2%. The average LI of "basal" cells was 8.3% (range 5.9-11.9%) and that of "suprabasal" cells was 13.8% range (3.2-29.5%). The basal layer of the skin (5 samples) contained 9.3% labeled cells (range 3.3-16.3%); the LI of suprabasal layers of skin was 21.3% (range 7.8-33.2%).
CONCLUSION: Both the frequency and the spatial distribution of S-phase cells are disordered in noninvolved epithelia in patients with head and neck tumors. These observations suggest that disordered proliferation may be an early consequence of field cancerization, a consequence that occurs prior to appearance of morphologically apparent hyperplasia or dysplasia.

Entities:  

Mesh:

Year:  1996        PMID: 8902565     DOI: 10.1002/(SICI)1097-0347(199611/12)18:6<522::AID-HED6>3.0.CO;2-4

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

1.  Association of TGFβ signaling with the maintenance of a quiescent stem cell niche in human oral mucosa.

Authors:  Claudia D Andl; Grégoire F Le Bras; Holli Loomans; Annette S Kim; Linli Zhou; Yuhang Zhang; Thomas Andl
Journal:  Histochem Cell Biol       Date:  2016-08-02       Impact factor: 4.304

2.  Analysis and pharmacological modulation of senescence in human epithelial stem cells.

Authors:  Vanessa Barbaro; Antonio Orvieto; Gualtiero Alvisi; Marina Bertolin; Filippo Bonelli; Thomas Liehr; Tigran Harutyunyan; Stefanie Kankel; Gordana Joksic; Stefano Ferrari; Elena Daniele; Diego Ponzin; Daniela Bettio; Leonardo Salviati; Enzo Di Iorio
Journal:  J Cell Mol Med       Date:  2022-06-15       Impact factor: 5.295

Review 3.  Divide and conquer: two stem cell populations in squamous epithelia, reserves and the active duty forces.

Authors:  Spencer Dunaway; Alexandra Rothaus; Yuhang Zhang; Ana Luisa Kadekaro; Thomas Andl; Claudia D Andl
Journal:  Int J Oral Sci       Date:  2019-08-27       Impact factor: 6.344

4.  Single-cell RNA-Seq of human esophageal epithelium in homeostasis and allergic inflammation.

Authors:  Mark Rochman; Ting Wen; Michael Kotliar; Phillip J Dexheimer; Netali Ben-Baruch Morgenstern; Julie M Caldwell; Hee-Woong Lim; Marc E Rothenberg
Journal:  JCI Insight       Date:  2022-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.